Blood, Vol. 94 No. 5 (September 1), 1999:
pp. 1561-1567
Interleukin-1
and Tumor Necrosis Factor-
Stimulate DNA Binding of
Hypoxia-Inducible Factor-1
By
Thomas Hellwig-Bürgel,
Karen Rutkowski,
Eric Metzen,
Joachim Fandrey, and
Wolfgang Jelkmann
From the Institut für Physiologie,
Medizinische Universität zu Lübeck,
Lübeck, Germany.
 |
ABSTRACT |
The rate of transcription of several genes encoding proteins
involved in O2 and energy homeostasis is controlled by
hypoxia-inducible factor-1 (HIF-1), a heterodimeric DNA binding complex
composed of
and
subunits. HIF-1 is considered the primary
trans-acting factor for the erythropoietin (EPO) and vascular
endothelial growth factor (VEGF) genes. Since EPO gene expression is
inhibited by the proinflammatory cytokines interleukin-1
(IL-1
)
and tumor necrosis factor-
(TNF-
), while no such effect has been
reported with respect to the VEGF gene, we investigated the effects of IL-1
and TNF-
on the activation of the HIF-1 DNA-binding complex and the amount of HIF-1
protein in human hepatoma cells in culture. Under normoxic conditions, both cytokines caused a moderate activation of HIF-1 DNA binding. In hypoxia, cytokines strongly increased HIF-1
activity compared with the effect of hypoxia alone. Only IL-1
increased HIF-1
protein levels. In transient transfection experiments, HIF-1-driven reporter gene expression was augmented by
cytokines only under hypoxic conditions. In contrast to their effect on
EPO synthesis, neither IL-1
nor TNF-
decreased VEGF production.
The mRNA levels of HIF-1
and VEGF were unaffected. Thus,
cytokine-induced inhibition of EPO production is not mediated by
impairment of HIF-1 function. We propose that HIF-1 may be involved in
modulating gene expression during inflammation.
© 1999 by The American Society of Hematology.
 |
INTRODUCTION |
ADAPTATION to reduced O2
availability involves the synthesis of proteins that systemically or
locally protect the organism from hypoxic damage.1,2 Thus,
at low pO2, the production of the glycoprotein
erythropoietin (EPO) increases to stimulate the proliferation and
differentiation of erythrocytic progenitors in bone marrow, resulting
in a greater O2 capacity of the blood.3,4 The
kidneys and liver are the main sites of production of the hormone.
Apart from renal failure, chronic inflammatory and malignant diseases
are often associated with normocytic and normochromic anemia, which is
partly caused by a lack of EPO.5,6 In vitro studies using
human hepatoma cells7-9 or isolated perfused rat kidneys8,10 have shown that the proinflammatory cytokines interleukin-1
(IL-1
) and tumor necrosis factor-
(TNF-
)
decrease EPO mRNA levels and inhibit hypoxia-induced EPO production, respectively.
Besides erythropoiesis, angiogenesis is also stimulated by hypoxia. The
most specific inducer of angiogenesis is vascular endothelial growth
factor (VEGF), which is produced by normal and malignant cells at low
pO2.11 Encoded in a single
gene, VEGF mRNA may exist as 4 or 5 different splice variants, with the
165-amino acid isoform (VEGF165) being the predominant
secreted form. VEGF and EPO synthesis share several regulatory
mechanisms,12 including the participation of a hemoprotein
as the O2 sensor and cis-acting elements that bind
to hypoxia-inducible factor-1 (HIF-1). However, while erythropoiesis is
suppressed in inflammatory states, angiogenesis is locally stimulated
as in wound-healing and solid-tumor formation. IL-1
and other
proinflammatory cytokines increase VEGF mRNA levels in several cell
lines.11
HIF-1 is a heterodimeric transcription factor composed of the basic
helix-loop-helix-PAS-domain (period, arylhydrocarbon receptor, single-minded) containing proteins HIF-1
and aryl
hydrocarbon receptor nuclear translocator
([ARNT] = HIF-1
).13,14 The main pO2-sensitive component of the complex appears to be
HIF-1
.15 Its rapid degradation under normoxic conditions
is probably mediated by the ubiquitin-proteasome system.16
Although ARNT may also increase in response to hypoxic
stress,14 its abundance is more constitutive than that of
HIF-1
. The fact that HIF-1
and ARNT transcripts and HIF-1 DNA
binding and trans-activating activity have been demonstrated in
all tissues investigated thus far underlines the importance of HIF-1 in
pO2-dependent gene expression.1,2,17
In the present investigation, the effects of IL-1
and TNF-
on
HIF-1 DNA binding activity, HIF-1
protein content, reporter gene
expression, and HIF-1
mRNA and VEGF mRNA levels in HepG2 cells were
studied. This human hepatoma cell line was chosen because it expresses
both the EPO and VEGF genes in a pO2-dependent
manner.12,18,19
 |
MATERIALS AND METHODS |
Cell culture.
The human hepatoma cell line HepG2 was obtained from the American Type
Culture Collection (Rockville, MD). The murine hepatoma cell line
Hepa-1 (kindly provided by Dr O. Hankinson, Los Angeles, CA) was used
to compare HIF-1 DNA-binding activity with different oligonucleotides.
The cells were grown in RPMI 1640 medium (HepG2) or
-minimal
essential medium without nucleosides (Hepa-1)
containing 10% fetal bovine serum (Sigma, Deisenhofen,
Germany) in a humidified atmosphere of 5% CO2 in air at
37°C, on either conventional polystyrene dishes (16- or 94-mm
diameter) or petriPERM tissue culture dishes (52-mm diameter;
Heraeus, Hanau, Germany). The bottom of the petriPERM dish is made of a gas-permeable fluoroethylene-propylene copolymer Teflon membrane of 25-µm thickness that allows adjustment of the pericellular pO2 to the pO2 level in the gas
atmosphere.19 In conventional dishes with a gas-impermeable
bottom, the pericellular pO2 decreases with increasing
culture density.20 Low-density cultures in polystyrene
dishes were placed in an incubator with 3% O2 (21 mm Hg),
5% CO2, and 92% N2 for hypoxic incubation.
Cells grown on petriPERM dishes were placed in a gas-tight acrylic
chamber at continuous flow of a premixed gas of 2% O2 (14 mm Hg), 5% CO2, and 93% N2 as described
previously.19,20 Cells received fresh medium 16 hours
before the experiments. The proinflammatory cytokines used for the
study were recombinant human IL-1
(Ciba-Geigy, Basel, Switzerland)
and recombinant human TNF-
(6.6 × 106 U/mg
by L929 bioassay; BASF/Knoll, Ludwigshafen, Germany).
Nuclear extract preparation.
Nuclear extracts were prepared according to the method of Semenza and
Wang21 with minor modifications. Hepa-1 cells were grown to
40% to 60% confluence and HepG2 cells to 20% to 30% confluence in
conventional cell culture dishes. In total, 4 to 5 × 107
cells were washed with ice-cold phosphate-buffered saline (PBS), harvested in 6 mL PBS, and centrifuged at 400 × g for 5 minutes at 4°C. The cell pellets were washed with 4 mL ice-cold
buffer A (10 mmol/L Tris, pH 7.8, 1.5 mmol/L MgCl2, and 10 mmol/L KCl), resuspended in 1 mL buffer A, and kept on ice for 10 minutes. Subsequently, cells were lysed by Dounce homogenization, and
lysis was controlled with trypan blue. Nuclei were pelleted at 3,500 × g for 5 minutes at 4°C, resuspended in 150 µL ice-cold
buffer C (420 mmol/L KCl, 20 mmol/L Tris, pH 7.8, 1.5 mmol/L
MgCl2, and 20% glycerol), and incubated for 30 minutes on
ice with occasional flicking of the tubes. Just before use, buffers A
and C were supplemented with 2 µg/mL aprotinin, 10 µg/mL leupeptin,
20 µg/mL pepstatin, 1 mmol/L Na3VO4, 0.5 mmol/L benzamidine, 2 mmol/L levamisole, 10 mmol/L
-glycerophosphate, 0.5 mmol/L dithiothreitol (DTT), and 0.4 mmol/L
phenylmethylsulfonyl fluoride. Nuclei were centrifuged at 12,000 × g for 30 minutes at 4°C. The supernatant was dialyzed against
1 L buffer D (100 mmol/L KCl, 20 mmol/L Tris, pH 7.8, 2 mmol/L EDTA,
and 20% glycerol) overnight at 4°C. After dialysis, nuclear extracts
were collected by brief centrifugation at 4°C, divided into aliquots,
and frozen in liquid nitrogen and stored at
80°C. Protein
concentrations were determined by the Bradford method using bovine
serum albumin as standard.
Gel-shift assay.
[
-32P]adenosine triphosphate (ATP) was obtained from
New England Nuclear (Köln, Germany).
Oligonucleotides for gel-shift assays were synthesized by EuroGenTec
(Seraing, Belgium) or MWG (Ebersberg, Germany).
Sequences containing HIF-1 binding sites were derived from the human
transferrin gene (TfHBSww) and the EPO enhancer (EpoWT). In the TfHBSww
enhancer, two HIF-1 binding sites are present.22 A mutated
HIF-1 binding site in another EPO enhancer oligonucleotide (EpoMut) was
used to demonstrate specificity. Sequences were as follows: TfHBSww
(sense), 5'-TTCCTGCACGTACACACAAAGCGCACGTATTTC-3'; TfHBSww (antisense),
5'-GAAATACGTGCGCTTTGTGTGTACGTGCAGGAA-3'; EpoWT (sense),
5'-GCCCTACGTGCTGCCTCGCATGGC-3'; EpoWT (antisense), 5'-GCCATGCGAGGCAGCACGTAGGGC-3'; EpoMut (sense),
5'-GCCCTAATGTCTGCCTCGCATGGC-3'; and EpoMut (antisense),
5'-GCCATGCGAGGCAGACATTAGGGC-3'. Anti-HIF-1
antibodies OZ12 and OZ15
were generously provided by Dr D. Livingston (Boston, MA). Binding
reactions were set up in a volume of 20 µL, and nuclear extracts (5 µg protein) were incubated in a buffer with a final concentration of
50 mmol/L KCl, 10 mmol/L Tris, pH 7.7, 5 mmol/L DTT, 1 mmol/L EDTA, 1 mmol/L MgCl2, 5% glycerol, 0.03% Nonidet P-40, and 400 ng
salmon testes DNA. Before addition of the 32P-labeled
oligonucleotide, the reactions were preincubated on ice for 30 minutes.
The final incubation was overnight at 4°C. Samples were resolved by
electrophoresis on 5% polyacrylamide gels
(polyacrylamide:bisacrylamide 30:0.8) at room temperature. Gels were
dried and analyzed directly by autoradiography. For competition
experiments, a 250-fold molar excess of unlabeled annealed
oligonucleotides were added before addition of the labeled probes. For
supershift experiments, undiluted anti-HIF-1
antibodies (5 µL
each) OZ12 and OZ15 were mixed and added to the reactions 2 hours
before the gel was run.
Western blot analysis.
For determination of immunoreactive HIF-1
protein in the nuclei of
cells, nuclear extracts were prepared as already described and
subjected to Western blot analysis. Samples were run on sodium dodecyl
sulfate (SDS)/7.5% polyacrylamide gels and transferred to
nitrocellulose membranes (Amersham, Braunschweig,
Germany) electrophoretically (Trans-Blot SD; BioRad, München,
Germany). Equal loading and transfer efficiency were verified by
staining with 2% Ponceau S. Membranes were blocked overnight with
PBS/5% fat-free skim milk and then incubated with a monoclonal mouse antibody raised against human HIF-1
(Transduction Laboratories, Lexington, KY) diluted 1:500 for 2 hours at room
temperature. For detection, a horseradish peroxidase-linked
anti-mouse IgG antibody (1:2,000, 1 hour at room temperature; Santa
Cruz, Heidelberg, Germany) and enhanced
chemiluminescence substrate (Amersham) were used.
Transfection and luciferase assay.
HepG2 cells (1.6 × 105) were seeded onto
8-cm2 cell culture dishes and grown to 25% to 50%
confluence. The medium was changed 3 hours before the cells were
transfected using the LIPOFECTIN reagent (Life Technologies,
Karlsruhe, Germany) and 1 µg of the reporter DNA
(pEpo-HIF plasmid) per dish. The pEpo-HIF plasmid was kindly provided
by T. Kietzmann (Göttingen, Germany) and corresponds to the
pGL3-promoter vector (Promega, Mannheim, Germany) with
a 46mer oligonucleotide containing 3 HIF-1 binding sites (HBSs) from
the EPO enhancer inserted 5' to the SV40 promoter. All transfections
were performed in duplicate with aliquots of transfection mixture from
a single pool. Eighteen hours after transfection, the medium was
changed and the cells were exposed to either normoxic or hypoxic
conditions with or without cytokines (10 ng/mL TNF-
or 300 pg/mL
IL-1
). After 24 hours, cells were washed twice with NaCl (0.9%) and
lysed in reporter lysis buffer (Promega). Luciferase activity was
determined according to the manufacturer's instructions (Berthold
Detection Systems, Pforzheim, Germany). Luminescence
was measured in a MicroLumat LB 96P (Berthold EG & G, Bad Wildbach, Germany).
Northern blot analysis.
HepG2 cells were grown either on petriPERM dishes (confluent
cultures) or on conventional cell culture dishes (20% to 30% confluence). Total RNA was isolated according to the method of Chomczynski and Sacchi.23 Samples were subjected to
electrophoresis in denaturing 1% agarose gels containing 0.7 mol/L
formaldehyde. RNAs were transferred onto nylon membranes (Nytran Plus;
Schleicher & Schüll, Dassel, Germany) with a
vacuum blotting apparatus (Pharmacia, Uppsala, Sweden). Filters were
cross-linked with UV light, dried at 80°C for 2 hours, and
prehybridized for 4 hours at 42°C in 45% formamide, 5× SSC, 5×
Denhardt solution, 0.1% SDS, and 100 µg/mL sonicated denatured
salmon testes DNA. Hybridizations were performed in fresh solution of
identical composition supplemented with the radioactive probe (0.5 to
2 × 106 cpm/mL) for 2 days at 42°C. Hybridization
probes were polymerase chain reaction (PCR)-generated fragments with
primers derived from the published cDNA sequences, with the exception
of the 18S rRNA probe, which was an antisense single-stranded DNA
oligonucleotide. PCR fragments were [
-32P]dCTP (New
England Nuclear)-labeled with a commercially available kit
(MBI-Fermentas, St Leon-Rot, Germany). The 18S rRNA
probe was labeled with [
-32P]ATP and T4 kinase. After
hybridization, the filters were washed twice for 15 minutes in 2×
SSC/0.1% SDS at 50°C and then twice in 0.1× SSC/0.1% SDS at
60°C. Filters were sealed in plastic bags and analyzed by exposure to
either Hyperfilm (Amersham) or imaging plates for a Bio Imaging
Analyzer (BAS 1000; Fuji, Düsseldorf, Germany).
Assay of EPO and VEGF.
The EPO level was measured in culture supernatants by
radioimmunoassay.8 The assay system contained
125I-labeled recombinant human EPO (137 TBq/mmol;
Amersham), antiserum raised in rabbits against
recombinant human EPO, and a human urinary EPO standard calibrated by
bioassay against the International Reference Preparation B. After 24 hours of incubation, antibody-bound and free radiolabeled EPO were
separated by precipitation with polyethylene glycol (PEG 6000). EPO
concentrations were calculated from log-logit plots of the standard
curves. The lower detection limit was 5 U/L. Intraassay and interassay
coefficients of variation were less than 6% and less than 12% in the
relevant range of 20 to 100 U/L.
The VEGF165 level was measured by commercial enzyme-linked
immunoassay (Quantikine; R&D Systems, Minneapolis, MN). The intraassay and interassay coefficients of variation were 5% and 7.5%, and the
lower detection limit was 9 pg/mL. EPO and VEGF concentrations were
related to the total cellular protein measured in lysates of washed
cultures using a protein microdetermination kit based on the phenol
reagent method (Sigma).
 |
RESULTS |
Effect of oligonucleotides on HIF-1 binding.
To study the effect of the number of HIF-1 binding sites (HBSs) within
the labeled annealed oligonucleotides used for gel mobility shifts,
oligonucleotides with 1 (EpoWT) and 2 (TfHBSww) functional HBSs were
used, respectively. Equimolar amounts of oligonucleotides were labeled
radioactively in parallel, annealed, and used in the binding reactions.
In nuclear extracts from Hepa-1 cells, hypoxia led to a clear induction
of the HIF-1 DNA binding complex as compared with normoxic conditions
(Fig 1, lanes 1 and 2). Signals from
hypoxic Hepa-1 cells obtained with TfHBSww (lane 3) were much stronger
than signals obtained with EpoWT (lane 4). The mouse hepatoma cell line
Hepa-1 was chosen because, upon hypoxic stimulation, Hepa-1 cells
accumulate large amounts of activated HIF-1 in the
nucleus.22 In nuclear extracts from hypoxic HepG2 cells
(human hepatoma cell line), HIF-1 binding to EpoWT was hardly detectable (data not shown).

View larger version (34K):
[in this window]
[in a new window]
| Fig 1.
Gel-shift analysis with nuclear extracts from Hepa-1
cells exposed to normoxia (lane 1) or hypoxia (3% O2 for 4 hours; lanes 2-6). HIF-1 DNA binding activity was examined with 3 different oligonucleotides containing either 2 (TfHBSww) or 1 (EpoWT)
consensus HBSs or a mutated HBS (EpoMut). For confirmation of
specificity, competition experiments were performed using a 250-fold
molar excess of unlabeled annealed TfHBSww oligonucleotide in the
binding reaction. HIF, inducible HIF-1 binding; c, constitutive
binding; n.s., nonspecific binding.
|
|
Specificity of HIF-1 binding was confirmed using EpoMut, an
oligonucleotide similar to EpoWT except for a mutated HBS. No HIF-1-specific signals, either the inducible band or the constitutive band, were obtained with EpoMut (Fig 1, lane 5). Furthermore, HIF-1
binding to labeled TfHBSww was strongly reduced when a 250-fold excess
of unlabeled TfHBSww was added (lane 6).
Influence of proinflammatory cytokines on HIF-1 activation.
To determine the nature of the inhibitory action of IL-1
and TNF-
on EPO gene expression, the effects of these cytokines on HIF-1 DNA
binding activity were analyzed in HepG2 cells. In nuclear extracts from
normoxic control cultures, faint inducible bands were observed in
slightly overexposed autoradiograms, indicating that some HIF-1
was
activated to form the DNA binding complex even under normoxic
conditions (Fig 2A and B, lane 1). Because these experiments were
performed on regular, gas-impermeable cell culture dishes, strict care
was taken to ensure that cultures did not exceed 20% to 30%
confluence and incubations were performed with 0.5-mm medium height to
ensure short diffusion distances. The effectiveness of this model
system was demonstrated by an increase in HIF-1 DNA binding activity
after 4 hours of hypoxia (Fig 2A, lane 3). IL-1
treatment resulted
in a significant increase in HIF-1 DNA binding both in normoxic cells
(Fig 2A, lane 2; compared with the normoxic control) and in hypoxic
cells (lane 4; compared with the hypoxic
control).

View larger version (68K):
[in this window]
[in a new window]
| Fig 2.
(A) Gel-shift analysis with nuclear extracts from HepG2
cells incubated under normoxic (20% O2) or hypoxic (3%
O2) conditions for 4 hours in the absence or presence of
IL-1 300 pg/mL. (B) Gel-shift analysis with nuclear extracts from
normoxic HepG2 cells and hypoxic HepG2 cells treated with TNF- 10 ng/mL or IL-1 300 pg/mL for 4 hours. Specificity was demonstrated in
a supershift experiment with anti-HIF-1 antibodies (AB). See Fig 1
for abbreviations.
|
|
TNF-
was as effective as IL-1
in augmenting hypoxia-induced HIF-1
binding (Fig 2B, lanes 3 and 4). Similar to IL-1
, albeit to a lesser
extent, TNF-
increased HIF-1 DNA binding in normoxic cells (not
shown). Evidence that HIF-1
was a component of the complex that
bound to DNA in TNF-
-treated hypoxic cells was provided by a
supershift analysis. The addition of a mixture of OZ12 and OZ15
antibodies (specific for HIF-1
protein) to binding reactions resulted in reduced electrophoretic mobility (Fig 2B, lane 5).
Influence of proinflammatory cytokines on HIF-1
protein level.
To determine whether the increased DNA binding activity after cytokine
treatment was based on elevated amounts of activated HIF-1
or on
coactivated proteins' being part of the DNA binding complex, Western
blot assays were performed. Incubation with IL-1
under either
normoxic or hypoxic conditions led to increased amounts of HIF-1
protein in the nuclei compared with the normoxic and hypoxic controls.
In contrast, TNF-
did not cause a significant accumulation of
HIF-1
protein within the nuclei (Fig 3).

View larger version (80K):
[in this window]
[in a new window]
| Fig 3.
Detection of HIF-1 protein by Western blot analysis.
Twenty micrograms of nuclear protein per lane was sufficient for
detection by a monoclonal anti-HIF-1 antibody. IL-1 caused an
accumulation of HIF-1 protein in nuclei from HepG2 cells under
normoxic and hypoxic conditions. TNF- was ineffective.
|
|
Action of cytokines on reporter gene expression.
To prove that the augmented HIF-1 DNA binding activity after cytokine
treatment is functional, reporter gene assays were performed. After
transfection of HepG2 cells with the pEpo-HIF plasmid, luciferase activity in cell extracts was determined. Hypoxia increased luciferase activity compared with normoxia (Fig 4).
Furthermore, cytokines amplified luciferase activity by 25% in hypoxic
cells (compared with hypoxia alone), whereas the cytokines had no
effect in normoxic cells.

View larger version (30K):
[in this window]
[in a new window]
| Fig 4.
(Top) Schematic drawing of the relevant parts of the
pEpo-HIF plasmid (not in scale). (Bottom) Typical result of a reporter
gene expression assay in HepG2 cells treated with either TNF- or
IL-1 under normoxic or hypoxic conditions. Relative light units were
normalized to the protein level per dish, and values are shown in
relation to the normoxic control (=100%).
|
|
Effect of cytokines on steady-state HIF-1
and VEGF
mRNA content.
Northern blot analyses on total RNAs from 20% to 30% confluent HepG2
cultures showed no changes in the HIF-1
steady-state mRNA content
during normoxic or hypoxic incubation. Additionally, no differences
were detectable when cells were treated with TNF-
or IL-1
(Fig
5). Because IL-1
and TNF-
affect VEGF
gene expression in other cell types,12 the filters were
reprobed with a VEGF-specific probe. No obvious changes in VEGF
steady-state mRNA content induced by cytokines were detected.
Furthermore, the 4-hour hypoxic incubation was apparently not
sufficient to increase VEGF mRNA levels in HepG2 cells under our
culture conditions.

View larger version (75K):
[in this window]
[in a new window]
| Fig 5.
Northern hybridizations with HIF-1 - and VEGF-specific
probes on total RNAs from HepG2 cells. Cultures were grown in
conventional culture dishes to 20%-30% confluence. Normoxic cells (N)
were incubated in 20% O2 and hypoxic cells (H) in 3%
O2 for 4 hours with TNF 10 ng/mL or IL-1 300 pg/mL.
The ethidium bromide fluorescence of the RNA is shown at the bottom.
Neither of the 2 cytokines had an effect on HIF-1 or VEGF mRNA
levels after 4 hours of incubation.
|
|
Effect of IL-1
and TNF-
on EPO and
VEGF production.
Confluent HepG2 cultures grown under conventional conditions in
gas-impermeable polystyrene dishes produced EPO and VEGF in large
amounts. Previous microelectrode measurements of the pericellular pO2 indicate that such cultures are hypoxic due to the
diffusion-limited O2 supply.19,20 The 24-hour
rate of production of immunoreactive EPO was decreased when either
IL-1
or TNF-
were added to the cultures. In contrast, these
cytokines did not alter the rate of production of VEGF (Table
1).
 |
DISCUSSION |
HIF-1 was initially identified as a dimeric hypoxia-inducible
transcription factor that interacts with the hypoxia-response element
of the hepatic EPO gene enhancer.13,14,21 Subsequently, HIF-1 has been shown to initiate transcription of several other pO2-controlled genes, including the VEGF gene. Because
IL-1
and TNF-
inhibit the synthesis of EPO but not VEGF, we
considered it of interest to study the effects of these proinflammatory
cytokines on HIF-1
mRNA and protein levels, as well as HIF-1 DNA
binding activity and transcriptional activation. The finding of
increased HIF-1 DNA binding following IL-1
or TNF-
treatment in
human hepatoma cells (HepG2) was unexpected. This may not only be
relevant with respect to O2 and energy homeostasis, because
recent studies have shown that HIF-1 is involved in hypoxia-mediated
apoptosis.24
Several mechanisms can contribute to the regulation of gene expression.
IL-1
and TNF-
have been found to reduce EPO mRNA levels in
hypoxic human hepatoma cells.7,9 The cytokines are thought
to act at the transcriptional level because they do not reduce the
half-life of EPO mRNA, which is 1.5 hours in hypoxic HepG2
cells.9 Since HIF-1 DNA binding was increased (Fig 2), the
inhibition of EPO gene expression by cytokines appears to be mediated
by other cis-acting elements. The augmented HIF-1 DNA binding
activity after IL-1
treatment can be attributed, at least in part,
to the increased HIF-1
protein level in the nuclei (Fig 3). On the
other hand, the effect of TNF-
on HIF-1 DNA binding is probably
mainly due to concomitant activation of other proteins that are part of
the activated complex. Cyclic adenosine monophosphate (cAMP)-responsive
element (CRE) binding-1 (CREB-1) protein has been shown to augment
hypoxia-induced activity of the HIF-1 site in the EPO gene
enhancer25,26 and to increase HIF-1-dependent lactate
dehydrogenase A gene transcription.27 HIF-1 binding element
and CRE are thought to overlap in the EPO 3' enhancer.26
Whether IL-1
and TNF-
interfere with CREB-1 binding is presently
unknown. Previous attempts have failed to demonstrate effects of these
cytokines on cAMP levels and protein kinase A activity in HepG2 cells,
although the addition of cAMP analog largely prevents the in vitro
inhibition of EPO production by IL-1
or TNF
.9
Transfection studies with HIF-1
and HIF-1
DNA constructs have
shown that overexpression of the HIF-1 protein alone does not increase
EPO production in either normoxic or hypoxic Hep3B cells.28
Moreover, other transcription factors are important for hypoxic gene
expression. The role of hepatic nuclear factor-4 (HNF-4), which binds
long-chain acyl-coenzyme A thioesters,29 in hypoxically
induced gene expression is only partly elucidated. But for full hypoxic
induction of the hepatic EPO gene, the binding of HNF-4 is
required.30 However, studies of the effects of IL-1
or
TNF-
on HNF-4 DNA binding have not been reported. Thus, it is not
surprising that our reporter gene assays have shown that increased
HIF-1 DNA binding activity is functional under hypoxic conditions only.
The 5' flanking region of the EPO gene contains a number of elements
potentially responsive to cytokines, including nuclear factor Kappa B
(NF
B) and GATA transcription factors binding
sites.1,31 NF
B is activated in HepG2 cells upon
treatment with IL-1
or TNF-
,32 but a suppressive role
in EPO gene expression has not been reported. GATA-2 binding represses
EPO gene transcription.33 Hydrogen peroxide, a putative
intracellular messenger between the O2 sensor and the EPO
gene,34 inhibits EPO production by increasing GATA-2 levels
in Hep3B cells.35 Thus, it must be considered that IL-1
and TNF-
may act by a similar mechanism.
In contrast to their effects on EPO production, IL-1
and TNF-
did
not decrease VEGF mRNA levels and VEGF production in HepG2 cells.
Others have found that IL-1 increases VEGF mRNA levels in smooth
muscle36 and fibroblasts.37,38 TNF-
is
effective in keratinocytes39 and the epidermoid carcinoma
line A-431.40 HIF-1 is considered the main
trans-acting factor in controlling the rate of transcription of
the VEGF gene.12,41 We propose that HIF-1 activation is
induced not only by hypoxia but also by the proinflammatory cytokines
IL-1
and TNF-
. If so, HIF-1 may play an important role not only
in oxygen and energy homeostasis but also in immune responses. For
instance, hepatic genes that can be activated by HIF-1 encode
acute-phase proteins42 and inducible nitric oxide
synthase.43 Our observation that cytokines can activate
HIF-1 in normoxic conditions emphasizes its possible role as a
trans-acting factor in inflammatory processes.
 |
ACKNOWLEDGMENT |
We are grateful to Dr O. Hankinson (Los Angeles, CA) and Dr D. Livingston (Boston, MA) for generously providing Hepa-1 cells and
anti-HIF-1
antibodies, respectively. We thank Dr A. Rolfs (Zürich, Switzerland) for assistance in setting up the HIF-1 electrophoretic mobility shift assay and Dr T. Kietzmann for providing the pEpo-HIF plasmid.
 |
FOOTNOTES |
Submitted November 16, 1998; accepted April 27, 1999.
Supported by a grant from the Deutsche Forschungsgemeinschaft (SFB
367-C8).
The publication costs of this
article were defrayed in part by
page charge payment. This article
must therefore be hereby marked
"advertisement"
in accordance with 18 U.S.C. section
1734 solely to indicate this fact.
Address reprint requests to Thomas Hellwig-Bürgel, Dipl-Biol,
Institut für Physiologie, Medizinische Universität zu
Lübeck, Ratzeburger Allee 160, D-23538 Lübeck, Germany;
e-mail: Hellwig{at}physio.mu-luebeck.de.
 |
REFERENCES |
1.
Bunn HF, Poyton RO:
Oxygen sensing and molecular adaptation to hypoxia.
Physiol Rev
76:839, 1996[Abstract/Free Full Text]
2.
Gleadle JM, Ratcliffe PJ:
Hypoxia and the regulation of gene expression.
Mol Med Today
3:122, 1998
3.
Krantz SB:
Erythropoietin.
Blood
77:419, 1991[Free Full Text]
4.
Jelkmann W:
Erythropoietin: Structure, control of production, and function.
Physiol Rev
72:449, 1992[Free Full Text]
5.
Means RT, Krantz SB:
Progress in understanding the pathogenesis of the anemia of chronic disease.
Blood
80:1639, 1992[Abstract/Free Full Text]
6.
Jelkmann W:
Proinflammatory cytokines lowering erythropoietin production.
J Interferon Cytokine Res
18:555, 1998[Medline]
[Order article via Infotrieve]
7.
Faquin WC, Schneider TJ, Goldberg MA:
Effect of inflammatory cytokines on hypoxia-induced erythropoietin production.
Blood
79:1987, 1992[Abstract/Free Full Text]
8.
Jelkmann W, Pagel H, Wolff M, Fandrey J:
Monokines inhibiting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneys.
Life Sci
50:301, 1992[Medline]
[Order article via Infotrieve]
9.
Fandrey J, Huwiler A, Frede S, Pfeilschifter J, Jelkmann W:
Distinct signaling pathways mediate phorbol-ester-induced and cytokine-induced inhibition of erythropoietin gene expression.
Eur J Biochem
226:335, 1994[Medline]
[Order article via Infotrieve]
10.
Frede S, Fandrey J, Pagel H, Hellwig T, Jelkmann W:
Erythropoietin gene expression is suppressed after lipopolysaccharide or interleukin-1
injections in rats.
Am J Physiol
273:R1067, 1997[Abstract/Free Full Text]
11.
Ferrara N, Davis-Smyth T:
The biology of vascular endothelial growth factor.
Endocr Rev
18:4, 1997[Abstract/Free Full Text]
12.
Goldberg MA, Schneider TJ:
Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin.
J Biol Chem
269:4355, 1994[Abstract/Free Full Text]
13.
Wang GL, Semenza GL:
Purification and characterization of hypoxia-inducible factor 1.
J Biol Chem
270:1230, 1995[Abstract/Free Full Text]
14.
Wang GL, Jiang BH, Rue EA, Semenza GL:
Hypoxia-inducible factor 1 is a basic helix-loop-helix-PAS heterodimer regulated by cellular O2 tension.
Proc Natl Acad Sci USA
92:5510, 1995[Abstract/Free Full Text]
15.
Huang LE, Arany Z, Livingston DM, Bunn HF:
Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its
-subunit.
J Biol Chem
271:32253, 1996[Abstract/Free Full Text]
16.
Salceda S, Caro J:
Hypoxia-inducible factor 1
(HIF-1
) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions.
J Biol Chem
272:22642, 1997[Abstract/Free Full Text]
17.
Wang GL, Semenza GL:
Oxygen sensing and response to hypoxia by mammalian cells.
Redox Rep
2:89, 1996
18.
Goldberg MA, Glass GA, Cunningham JM, Bunn HF:
The regulated expression of erythropoietin by two human hepatoma cell lines.
Proc Natl Acad Sci USA
84:7972, 1987[Abstract/Free Full Text]
19.
Wolff M, Fandrey J, Jelkmann W:
Microelectrode measurements of pericellular pO2 in erythropoietin-producing human hepatoma cell cultures.
Am J Physiol
265:C1266, 1993[Abstract/Free Full Text]
20.
Metzen E, Wolff M, Fandrey J, Jelkmann W:
Pericellular PO2 and O2 consumption in monolayer cell cultures.
Respir Physiol
100:101, 1995[Medline]
[Order article via Infotrieve]
21.
Semenza GL, Wang GL:
A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation.
Mol Cell Biol
12:5447, 1992[Abstract/Free Full Text]
22.
Rolfs A, Kvietikova I, Gassmann M, Wenger RH:
Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1.
J Biol Chem
272:20055, 1997[Abstract/Free Full Text]
23.
Chomczynski P, Sacchi N:
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.
Anal Biochem
162:156, 1987[Medline]
[Order article via Infotrieve]
24.
Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P, Moons L, Jain RK, Collen D, Keshert E:
Role of HIF-1
in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis.
Nature
394:485, 1998[Medline]
[Order article via Infotrieve]
25.
Kvietikova I, Wenger RH, Marti HH, Gassmann M:
The transcription factors ATF-1 and CREB-1 bind constitutively to the hypoxia-inducible factor-1 (HIF-1) DNA recognition site.
Nucleic Acids Res
23:4542, 1995[Abstract/Free Full Text]
26.
Kvietikova I, Wenger RH, Marti HH, Gassmann M:
The hypoxia-inducible factor-1 DNA recognition site is cAMP-responsive.
Kidney Int
51:564, 1997[Medline]
[Order article via Infotrieve]
27.
Firth JD, Ebert BL, Ratcliffe PJ:
Hypoxic regulation of lactate dehydrogenase A.
J Biol Chem
270:21021, 1995[Abstract/Free Full Text]
28.
Madan A, Varma S, Cohen HJ:
Co-transactivation of the 3' erythropoietin hypoxia inducible enhancer by the HIF-1 protein.
Blood Cell Mol Dis
23:169, 1997[Medline]
[Order article via Infotrieve]
29.
Hertz R, Magenheim J, Bermann I, Bar-Tana J:
Fatty acyl-CoA thioesters are ligands of hepatic nuclear factor-4
.
Nature
392:512, 1998[Medline]
[Order article via Infotrieve]
30.
Galson DL, Tsuchiya DS, Tendler LE, Huang LE, Ren Y, Ogura T, Bunn HF:
The orphan receptor hepatic nuclear factor 4 functions as a transcriptional activator for tissue-specific and hypoxia-specific erythropoietin gene expression and is antagonized by EAR3/COUP-TF1.
Mol Cell Biol
15:2135, 1995[Abstract]
31.
Lee-Huang S, Lin J-J, Kung H, Huang PL, Lee L, Huang PL:
The human erythropoietin-encoding gene contains a CAAT box, TATA boxes and other transcriptional regulatory elements in its 5' flanking region.
Gene
128:227, 1993[Medline]
[Order article via Infotrieve]
32.
Jelkmann W, Hellwig-Buergel T:
Tumor necrosis factor p55 receptor (TNF-RI) mediates the in vitro inhibition of hepatic erythropoietin production.
Exp Hematol
27:224, 1999[Medline]
[Order article via Infotrieve]
33.
Imagawa S, Izumi T, Miura Y:
Positive and negative regulation of the erythropoietin gene.
J Biol Chem
269:9038, 1994[Abstract/Free Full Text]
34.
Fandrey J, Frede S, Jelkmann W:
Role of hydrogen peroxide in hypoxia-induced erythropoietin production.
Biochem J
303:507, 1994
35.
Imagawa S, Yamamoto M, Ueda M, Miura Y:
Erythropoietin gene expression by hydrogen peroxide.
Int J Hematol
64:189, 1996[Medline]
[Order article via Infotrieve]
36.
Li J, Perrella MA, Tsai J-C, Yet S-F, Hsieh C-M, Yoshizumi M, Patterson C, Endego WO, Zhou F, Lee M-E:
Induction of vascular endothelial growth factor gene expression by interleukin-1
in rat aortic smooth muscle cells.
J Biol Chem
270:308, 1995[Abstract/Free Full Text]
37.
Ben-Av P, Crofford LJ, Wilder RL, Hla T:
Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: A potential mechanism for inflammatory angiogenesis.
FEBS Lett
372:83, 1995[Medline]
[Order article via Infotrieve]
38.
Jackson JR, Minton JAL, Ho ML, Wie N, Winkler JD:
Expression of vascular endothelial growth factor in synovial fibroblasts is induced by hypoxia and interleukin 1
.
J Rheumatol
24:1253, 1997[Medline]
[Order article via Infotrieve]
39.
Frank S, Hübner G, Breier G, Longaker MT, Greenhalgh DG, Werner S:
Regulation of vascular endothelial growth factor expression in cultured keratinocytes.
J Biol Chem
270:12607, 1995[Abstract/Free Full Text]
40.
Cohen T, Nahari D, Weiss Cerem L, Neufeld G, Levi B-Z:
Interleukin 6 induces the expression of vascular endothelial growth factor.
J Biol Chem
271:736, 1996[Abstract/Free Full Text]
41.
Forsythe JA, Jiang B-H, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL:
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1.
Mol Cell Biol
16:4604, 1996[Abstract]
42.
Wenger RH, Rolfs A, Marti HH, Bauer C, Gassmann M:
Hypoxia, a novel inducer of acute phase gene expression in a human hepatoma cell line.
J Biol Chem
270:27865, 1995[Abstract/Free Full Text]
43.
Melillo G, Taylor LS, Brooks A, Musso T, Cox GW, Varesio L:
Functional requirement of the hypoxia-responsive element in the activation of the inducible nitric oxide synthase promoter by the iron chelator desferrioxamine.
J Biol Chem
272:12236, 1997[Abstract/Free Full Text]